Cat. No.: HY-A0003

Lenalidomide

(Synonyms: CC-5013)

62 Cited Publications

Customer Review

Based on 62 publication(s) in Google Scholar

Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 191732-72-6
Formula: C₁₃H₁₃N₃O₃
Molecular Weight:259.26

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Lenalidomide Chemical Structure

CAS No.: 191732-72-6

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (62)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[5]

Cereblon

All Ligands for E3 Ligase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
EC9706	IC₅₀	340.3 μg/mL Compound: Lenalidomide	Antiproliferative activity against human EC9706 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human EC9706 cells after 48 hrs by CCK-8 assay	[PMID: 28757066]
G-401	IC₅₀	>10 μM Compound: Lenalidomide	Inhibition of cell viability in human G-401 cells incubated for 4 days by CellTiter-Glo luminescent cell viability assay Inhibition of cell viability in human G-401 cells incubated for 4 days by CellTiter-Glo luminescent cell viability assay	[PMID: 39132814]
HCC827	IC₅₀	>10 μM Compound: Lenalidomide	Antiproliferative activity against human HCC827 cells harboring EGFRDel19 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFRDel19 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31951960]
HEK293	IC₅₀	5.19 μM Compound: Lenalidomide	Inhibition of BRD4 bromodomain 2 (unknown origin) in HEK293 cells cotransfected with eGFP by flow cytometry based mCherry reporter gene analysis Inhibition of BRD4 bromodomain 2 (unknown origin) in HEK293 cells cotransfected with eGFP by flow cytometry based mCherry reporter gene analysis	[PMID: 32550984]
JeKo-1	IC₅₀	>20000 nM Compound: 1	Antiproliferative activity against human JeKo1 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human JeKo1 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
JeKo-1	IC₅₀	>20000 nM Compound: Lenalidomide	Antiproliferative activity against human Jeko-1 cells expressing CRBN-knockout assessed as cell viability measured after 7 days by CCK-8 assay Antiproliferative activity against human Jeko-1 cells expressing CRBN-knockout assessed as cell viability measured after 7 days by CCK-8 assay	[PMID: 35635954]
JeKo-1	IC₅₀	>20000 nM Compound: Lenalidomide	Antiproliferative activity against human Jeko-1 cells assessed as cell viability measured after 7 days by CCK-8 assay Antiproliferative activity against human Jeko-1 cells assessed as cell viability measured after 7 days by CCK-8 assay	[PMID: 35635954]
K562	IC₅₀	>10 μM Compound: Lenalidomide	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34217059]
K562	IC₅₀	>10 μM Compound: Lenalidomide	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 2 days by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 2 days by CCK8 assay	[PMID: 36306539]
Kasumi 1	IC₅₀	>20000 nM Compound: 1	Antiproliferative activity against human Kasumi-1 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human Kasumi-1 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
MCF-10A	IC₅₀	>20 μM Compound: Lenalidomide	Cytotoxicity against human MCF10A cells after 72 hrs by MTS assay Cytotoxicity against human MCF10A cells after 72 hrs by MTS assay	[PMID: 29795767]
MCF7	IC₅₀	>100 μM Compound: Len	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
MDA-MB-231	IC₅₀	>100 μM Compound: Len	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
MDA-MB-468	IC₅₀	>100 μM Compound: Len	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
MM1.S	IC₅₀	50 nM Compound: 1	Antiproliferative activity against human MM1S cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human MM1S cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
MM1.S	IC₅₀	0.081 μM Compound: Lenalidoamide	Antiproliferative activity against human MM1.S cells assessed as reduction in cell growth measured after 7 days culturing by CellTiter 96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human MM1.S cells assessed as reduction in cell growth measured after 7 days culturing by CellTiter 96 Aqueous non-radioactive cell proliferation assay	[PMID: 33328101]
MM1.S	IC₅₀	70.17 nM Compound: Lenalidomide	Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 7 days by CCK-8 assay Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 7 days by CCK-8 assay	[PMID: 35635954]
MM1.S	IC₅₀	>20000 nM Compound: Lenalidomide	Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 3 days by CCK-8 assay Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 3 days by CCK-8 assay	[PMID: 35635954]
MV4-11	IC₅₀	>20000 nM Compound: Lenalidomide	Antiproliferative activity against human MV411 cells after 72 hrs by MTS assay Antiproliferative activity against human MV411 cells after 72 hrs by MTS assay	[PMID: 29795767]
MV4-11	IC₅₀	>20000 nM Compound: 1	Antiproliferative activity against human MV411 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human MV411 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
MX1	IC₅₀	>100 μM Compound: Len	Antiproliferative activity against human MX1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MX1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
NAMALVA	IC₅₀	0.36 μM Compound: 1	Antiproliferative activity against human NAMALWA cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs by scintillation counting Antiproliferative activity against human NAMALWA cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs by scintillation counting	[PMID: 23168019]
PBMC	IC₅₀	0.1 μM Compound: 1	Inhibition of TNF-alpha production in LPS-stimulated human PBMC preincubated for 1 hr before LPS challenge measured after 28 to 20 hrs by ELISA Inhibition of TNF-alpha production in LPS-stimulated human PBMC preincubated for 1 hr before LPS challenge measured after 28 to 20 hrs by ELISA	[PMID: 23168019]
PBMC	IC₅₀	100 nM Compound: 1	Antiinflammatory activity in human PBMC cells assessed as reduction in LPS-induced TNF-alpha production preincubated for 1 hr followed by LPS addition and measured after 18 to 20 hrs by ELISA Antiinflammatory activity in human PBMC cells assessed as reduction in LPS-induced TNF-alpha production preincubated for 1 hr followed by LPS addition and measured after 18 to 20 hrs by ELISA	[PMID: 31125896]
PBMC	IC₅₀	>20000 nM Compound: 1	Cytotoxicity against human PBMC cells by CellTiter96 Aqueous non-radioactive cell proliferation assay Cytotoxicity against human PBMC cells by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
PBMC	IC₅₀	100 nM Compound: 11; CC-5013	Inhibition of TNF-alpha release in LPS stimulated human PBMC Inhibition of TNF-alpha release in LPS stimulated human PBMC	[PMID: 33906050]
Raji	IC₅₀	>20000 nM Compound: 1	Antiproliferative activity against human Raji cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human Raji cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
RPMI-8226	IC₅₀	>20000 nM Compound: 1	Antiproliferative activity against human RPMI8226 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human RPMI8226 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
T-cell	EC₅₀	0.15 μM Compound: 1	Inhibition of IL-2 production in human T cells measured after 2 to 3 days by ELISA Inhibition of IL-2 production in human T cells measured after 2 to 3 days by ELISA	[PMID: 23168019]
THP-1	IC₅₀	>20000 nM Compound: 1	Antiproliferative activity against human THP1 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human THP1 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
U-266	IC₅₀	>20000 nM Compound: 1	Antiproliferative activity against human U266 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human U266 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
WI-38	IC₅₀	>20 μM Compound: Lenalidomide	Cytotoxicity against human WI38 cells after 72 hrs by MTS assay Cytotoxicity against human WI38 cells after 72 hrs by MTS assay	[PMID: 29795767]
Z-138	IC₅₀	>20000 nM Compound: 1	Antiproliferative activity against human Z138 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human Z138 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]

In Vitro

Lenalidomide is potent in stimulating T cell proliferation and IFN-γ and IL-2 production. Lenalidomide has been shown to inhibit production of pro inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and elevate the production of anti-inflammatory cytokine IL-10 from human PBMCs. Lenalidomide downregulates the production of IL-6 directly and also by inhibiting multiple myeloma (MM) cells and bone marrow stromal cells (BMSC) interaction, which augments the apoptosis of myeloma cells^[2]. Dose-dependent interaction with the CRBN-DDB1 complex is observed with Thalidomide, Lenalidomide and Pomalidomide, with IC₅₀ values of ~30 μM, ~3 μM and ~3 μM, respectively, These reduced CRBN expression cells (U266-CRBN₆₀ and U266-CRBN₇₅) are less responsive than the parental cells to antiproliferative effects Lenalidomide across a dose-response range of 0.01 to 10 μM^[3]. Lenalidomide, a thalidomide analog, functions as a molecular glue between the human E3 ubiquitin ligase cereblon and CKIα is shown to induce the ubiquitination and degradation of this kinase, thus presumably killing leukemic cells by p53 activation^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The toxicity of Lenalidomide doses up to 15, 22.5, and 45 mg/kg via IV, IP, and PO routes of administration. Limited by solubility in our PBS dosing vehicle, these maximum achievable Lenalidomide doses are well tolerated with the exception of one mouse death (of four total dosed) at the 15 mg/kg IV dose. Notably, no other toxicities are observed in the study at IV doses of 15 mg/kg (n=3) or 10 mg/kg (n=45) or at any other dose level through IV, IP, and PO routes^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 191732-72-6
Appearance Solid
Molecular Weight 259.26
Formula C₁₃H₁₃N₃O₃
Color Off-white to light yellow
SMILES

O=C1C2=CC=CC(N)=C2CN1C(C(N3)=O)CCC3=O
Synonyms

CC-5013
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (62)

All WB

Sort by:

Journal Impact Factor

Nature

Fate induction in CD8 CAR T cells through asymmetric cell division. [Abstract]

2024 Sep;633(8030):670-677. PMID: 39198645
Cancer Cell

High-performance multiplex drug-gated CAR circuits. [Abstract]

2022 Nov 14;40(11):1294-1305.e4. PMID: 36084652
Cell

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. [Abstract]

2018 Sep 20;175(1):171-185.e25. PMID: 30146162

Lenalidomide purchased from MedChemExpress. Usage Cited in: Cell. 2018 Sep 20;175(1):171-185.e25. [Abstract]

WB analysis of MV4-11 cells treated for 6.5 hr with Lenalidomide, BTX161, A51, or A86 at the indicated concentrations or DMSO.
Nat Cancer

IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. [Abstract]

2022 May;3(5):595-613. PMID: 35534777

Lenalidomide purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 May;3(5):595-613. [Abstract]

Western blot analysis for IKAROS, CK1α and MENIN protein following treatment of MV4;11 human MLL-r AML cell line for 5 hours with increasing doses of Thalidomide, lenalidomide, Pomalidomide and iberdomide (10,100, 1000 nM), using ACTIN as a loading control.
Cancer Res

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia. [Abstract]

2025 Jan 2;85(1):101-117. PMID: 39437162
Nat Commun

Tissue-resident macrophage survival depends on mitochondrial function regulated by SerpinB2 in chronic inflammation. [Abstract]

2026 Feb 12;17(1):1493. PMID: 41680163
Nat Commun

PROTAC repurposing uncovers a noncanonical binding surface that mediates chemical degradation of nuclear receptors. [Abstract]

2025 Nov 6;16(1):9805. PMID: 41198675
Nat Commun

Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation. [Abstract]

2025 Sep 1;16(1):8155. PMID: 40890111
Nat Commun

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase. [Abstract]

2017 May 22;8:15398. PMID: 28530236

Lenalidomide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 May 22;8:15398. [Abstract]

HEK293T cells are treated with 50 μg/mL Cycloheximide and increasing concentrations of Lenalidomide, Thalidomide or with DMSO, and cells are incubated for 6 h. ZFP91 and GAPDH levels are detected using anti-ZFP91 or anti-GAPDH immunoblotting.
Adv Sci (Weinh)

Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. [Abstract]

2026 Apr;13(21):e18975. PMID: 41655233
Nat Chem Biol

Acute pharmacological degradation of Helios destabilizes regulatory T cells. [Abstract]

2021 Jun;17(6):711-717. PMID: 34035522
Leukemia

Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma. [Abstract]

2025 Mar;39(3):720-733. PMID: 39885295
Microbiome

Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy. [Abstract]

2025 Feb 28;13(1):56. PMID: 40022244
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Rep Med

STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma. [Abstract]

2024 Mar 19;5(3):101472. PMID: 38508140
Cell Commun Signal

IKZF1 as a potential therapeutic target for dendritic cell-mediated immunotherapy in IgA nephropathy. [Abstract]

2025 May 7;23(1):216. PMID: 40336063
Int J Biol Macromol

2026 Jan 7;340:150099.
Acta Pharmacol Sin

Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma. [Abstract]

2025 Mar 25. PMID: 40133626
Acta Pharmacol Sin

The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L. [Abstract]

2020 Sep;41(9):1246-1254. PMID: 32210356
Free Radic Biol Med

Targeting ABCB6 with nitidine chloride inhibits PI3K/AKT signaling pathway to promote ferroptosis in multiple myeloma. [Abstract]

2023 Jul:203:86-101. PMID: 37044150
Neoplasia

Cholesterol biosynthesis as a drug-induced vulnerability in diffuse large B cell lymphoma insensitive to EZH2 inhibition. [Abstract]

2025 Oct 27:70:101243. PMID: 41151153
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
J Transl Med

Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis. [Abstract]

2024 Dec 3;22(1):1095. PMID: 39623468
Cell Rep

Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma. [Abstract]

2024 May 8;43(5):114211. PMID: 38722741
J Med Chem

Real-Time NanoBRET Target Engagement Reveals Permeability-Activity Relationships in BET-Targeting Degraders. [Abstract]

2026 May 28;69(10):12669-12677. PMID: 42139371
Elife

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. [Abstract]

2018 Aug 1;7:e38430. PMID: 30067223

Lenalidomide purchased from MedChemExpress. Usage Cited in: Elife. 2018 Aug 1;7:e38430. [Abstract]

H9 hESC are treated with increasing concentrations of Thalidomide, Lenalidomide, Pomalidomide, or DMSO as a control. Following 24 h of incubation, SALL4 and GAPDH protein levels are assessed by western blot analysis.
Mol Ther Oncol

Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDs. [Abstract]

2025 Feb 20;33(1):200952. PMID: 40123976
Inflammation

Progranulin Promotes Regeneration of Inflammatory Periodontal Bone Defect in Rats via Anti-inflammation, Osteoclastogenic Inhibition, and Osteogenic Promotion. [Abstract]

2019 Feb;42(1):221-234. PMID: 30187338
Int J Mol Sci

Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma. [Abstract]

2023 Sep 14;24(18):14097. PMID: 37762399
Front Cell Infect Microbiol

Lenalidomide potentially reduced the level of cell- associated HIV RNA and improved persistent inflammation in patients with HIV-associated cryptococcal meningitis a pilot study. [Abstract]

2022 Jul 28;12:954814. PMID: 35967862
Eur J Pharmacol

Doxorubicin-mediated retardation of aggresome formation enhances Carfilzomib-induced cell death synergistically by augmenting ER stress and proapoptotic signaling. [Abstract]

2025 Dec 5:1008:178303. PMID: 41183585
Int Immunopharmacol

Pomalidomide promotes macrophage control of Mycobacterium tuberculosis via enhancing HDAC6-mediated autophagy. [Abstract]

2025 May 14:158:114831. PMID: 40373598
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Cancers (Basel)

Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma. [Abstract]

2024 Mar 28;16(7):1319. PMID: 38610997
ACS Omega

Dynamic Detection of the E3-PROTAC-Target Protein Ternary Complex In Vitro and In Vivo via Bimolecular Fluorescence Complementation. [Abstract]

2024 Dec 3;9(50):49739-49748. PMID: 39713624
Cancer Sci

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways. [Abstract]

2019 Dec;110(12):3802-3810. PMID: 31583781
Biochim Biophys Acta Mol Basis Dis

Dengue virus is involved in insulin resistance via the downregulation of IRS-1 by inducing TNF-α secretion. [Abstract]

2022 Oct 1;1868(10):166472. PMID: 35752384
iScience

Identification of a drug-response gene in multiple myeloma through longitudinal single-cell transcriptome sequencing. [Abstract]

2022 Jul 19;25(8):104781. PMID: 35992084
Oncol Rep

Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro. [Abstract]

2018 Jun;39(6):2873-2880. PMID: 29693175

Lenalidomide purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Jun;39(6):2873-2880. [Abstract]

Representative western blot membranes showing the expression levels of NF-κB p-p65 and H3 in nuclear protein and of NF-κB p65 and β-actin in total protein. β-actin and H3 are used as internal controls.
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
ACS Pharmacol Transl Sci

General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex. [Abstract]

2021 Feb 26;4(2):941-952. PMID: 33860212
Am J Pathol

Pathophysiological function of endogenous calcitonin gene-related peptide in ocular vascular diseases. [Abstract]

2015 Jun;185(6):1783-94. PMID: 25857228
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Food Chem Toxicol

Inorganic arsenic induces pyroptosis and pancreatic β cells dysfunction through stimulating the IRE1α/TNF-α pathway and protective effect of taurine. [Abstract]

2019 Mar:125:392-402. PMID: 30660605
Clin Chim Acta

Detection of lenalidomide metabolites in urine to discover drug-resistant compounds. [Abstract]

2024 Jan 15:553:117707. PMID: 38103853
SSRN

2026 Jun 16.
Charles University

2026.
bioRxiv

Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cells. [Abstract]

2026 Feb 8:2026.02.06.704516. PMID: 41822826
Chemrxiv

2025 Nov 17.
Harvard University

2025.
bioRxiv

2024 October 19.
Patent

US20240261246A1.
bioRxiv

2024 June 12.
Universidad de Navarra

2024 Feb 28.
Patent

US20220332776A1.
Oxid Med Cell Longev

TNF- α Induces Neutrophil Apoptosis Delay and Promotes Intestinal Ischemia-Reperfusion-Induced Lung Injury through Activating JNK/FoxO3a Pathway. [Abstract]

2021 Dec 29:2021:8302831. PMID: 35003520
Patent

US20210379039A1.
University of Washington

2021 Aug 31.
bioRxiv

April.
Patent

US20180263995A1.
Patent

US20170360780A1.
Masaryk University

2014.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (385.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.8571 mL

19.2857 mL

38.5713 mL

5 mM

0.7714 mL

3.8571 mL

7.7143 mL

10 mM

0.3857 mL

1.9286 mL

3.8571 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[3]

Cell lines NCI-H929 and U266, and DF15 cells are grown in RPMI-I640 medium containing 10% (V/V) heat-inactivated fetal bovine serum supplemented with 2 mM glutamine. To produce Lenalidomide resistant cell lines, NCI-H929 cells are treated continuously (fresh Lenalidomide is added every 3-4 days) with control (final 0.1% DMSO) or low-dose Lenalidomide (1 μM) for 2 months until the proliferation of cells is no longer inhibited by Lenalidomide (1 μM), as determined by cell viability (Vi-cell XR cell viability analyzer), cell proliferation by flow cytometry and cell cycle analysis (propidium iodide staining). After acquisition of resistance to 1 μM, the resistant H929 cell lines are treated with Lenalidomide (10 μM) for a further 4 months. After this period of time, the cell cultures achieved fully establish resistance up to high-dose Lenalidomide (30 μM). Prior to the experiments described here, H929 Lenalidomide-resistant cells are taken out of culture with compounds for 5-7 days before use^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Mice^[4]
Imprinting control region (ICR) mice 8-10 weeks of age are used. Lenalidomide is incompletely soluble at 3.5 mg/mL and above in PBS containing 1% HCl, as visible particulates remained after thorough mixing. Therefore 3 mg/mL is selected as the maximum dosing solution concentration (with no visible particulates). Single, individual mice are initially dosed with 3, 10, or 15 mg/kg IV; 4.5, 15, or 22.5 mg/kg IP; and 9, 30, or 45 mg/kg PO. Additional mice (n=4) are then evaluated at the maximum dose achievable by volume and solubility of Lenalidomide in the dosing solution. All mice are monitored closely for 1 h and re-evaluated for toxicities 3, 6, and 24 h postdose^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)

SDS (418 KB)

English - EN (418 KB)

Français - FR (418 KB)

Deutsch - DE (418 KB)

Norwegian - NO (418 KB)

Español - ES (418 KB)

Swedish - SV (418 KB)

Italian - IT (418 KB)

Portuguese - PT (418 KB)

COA (2659 KB)

Elemental Analysis Report (2659 KB)

HNMR (2659 KB)

CNMR (2659 KB)

RP-HPLC (2659 KB)

NP-HPLC (2659 KB)

MS (2659 KB)

LCMS (2659 KB)

IR (2659 KB)

GC (2659 KB)

OR (2659 KB)

SDS-PAGE (2659 KB)

SEC-HPLC (2659 KB)

Other Report (2659 KB)

Handling Instructions (2659 KB)

References

[1]. Krönke J, et al. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology. 2014 Jul 3;3(7):e941742. [Content Brief]

[2]. Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009 Aug 12;2:36. [Content Brief]

[3]. Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. [Content Brief]

[4]. Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14(4):872-82. [Content Brief]

[5]. Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25. [Content Brief]

[6]. Nagashima, Takeyuki, et al. PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT. Patent. 20170360780A1.

[7]. Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. ScientificWorldJournal. 2013 Sep 21;2013:208309. [Content Brief]

View More

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg

DMSO 1 mM 3.8571 mL 19.2857 mL 38.5713 mL 96.4283 mL

5 mM 0.7714 mL 3.8571 mL 7.7143 mL 19.2857 mL

10 mM 0.3857 mL 1.9286 mL 3.8571 mL 9.6428 mL

15 mM 0.2571 mL 1.2857 mL 2.5714 mL 6.4286 mL

20 mM 0.1929 mL 0.9643 mL 1.9286 mL 4.8214 mL

25 mM 0.1543 mL 0.7714 mL 1.5429 mL 3.8571 mL

30 mM 0.1286 mL 0.6429 mL 1.2857 mL 3.2143 mL

40 mM 0.0964 mL 0.4821 mL 0.9643 mL 2.4107 mL

50 mM 0.0771 mL 0.3857 mL 0.7714 mL 1.9286 mL

60 mM 0.0643 mL 0.3214 mL 0.6429 mL 1.6071 mL

80 mM 0.0482 mL 0.2411 mL 0.4821 mL 1.2054 mL

100 mM 0.0386 mL 0.1929 mL 0.3857 mL 0.9643 mL

Lenalidomide Related Classifications

Cat. No.: HY-A0003

PROTAC Apoptosis

Ligands for E3 Ligase Molecular Glues Apoptosis

Disease Areas

Cancer Infection Inflammation or Immune System Disease Blood or Cardio-cerebrovascular Disease Digestive System Disease Urogenital Disease Neurological, Eye or Ear Disease

Coronavirus Infection Prostate Cancer Urogenital Cancer Leukemia/Lymphoma/Myeloma Blood Disease Pancreatic Cancer Digestive System Cancer Viral Infection Digestive System Inflammation

SARS-CoV-2 Infection

Inflammation/Immunology Cancer

Cancer Targeted Therapy Cancer Immunotherapy Cancer Metabolism and Metastasis

Powered by Bioz See more details on Bioz

Keywords

Lenalidomide
191732-72-6
CC-5013
CC5013
CC 5013
Ligands for E3 Ligase
Molecular Glues
Apoptosis
degradation
IKZF1
IKZF3
multiple
myeloma
analog
immunomodulatory
E3
ligase
cereblon
CRL4
ligand
Inhibitor
inhibitor
inhibit

Your Recently Viewed Products

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.8571 mL	19.2857 mL	38.5713 mL	96.4283 mL
5 mM	0.7714 mL	3.8571 mL	7.7143 mL	19.2857 mL
10 mM	0.3857 mL	1.9286 mL	3.8571 mL	9.6428 mL
15 mM	0.2571 mL	1.2857 mL	2.5714 mL	6.4286 mL
20 mM	0.1929 mL	0.9643 mL	1.9286 mL	4.8214 mL
25 mM	0.1543 mL	0.7714 mL	1.5429 mL	3.8571 mL
30 mM	0.1286 mL	0.6429 mL	1.2857 mL	3.2143 mL
40 mM	0.0964 mL	0.4821 mL	0.9643 mL	2.4107 mL
50 mM	0.0771 mL	0.3857 mL	0.7714 mL	1.9286 mL
60 mM	0.0643 mL	0.3214 mL	0.6429 mL	1.6071 mL
80 mM	0.0482 mL	0.2411 mL	0.4821 mL	1.2054 mL
100 mM	0.0386 mL	0.1929 mL	0.3857 mL	0.9643 mL

Lenalidomide

62 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Subscribe

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Lenalidomide

Apoptosis Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Ubiquitination Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Transcription Factor-Targeted Library

Rare Diseases Drug Library

Protein-protein Interaction Inhibitor Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

E3 Ligase Ligand Library

Non-steroidal Anti-Inflammatory Compound Library

Molecular Glue Compound Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Posttranslational Modification Library

Nephrotoxicity Compound Library

RNA Binding Bioactive Compound Library

Classic FDA-Approved Drug Library

3D Diverse Fragment Library

MCE Kinase Hinge Binder Fragment Library

Molecular Glue-like Compound Library

Publications Citing Use of MedChemExpress (MCE) Lenalidomide

All Ligands for E3 Ligase Isoforms

Biological Activity

Chemical Information

Publications (62)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Lenalidomide Related Classifications

Cat. No.: HY-A0003